Topic: Generic Health Relevance and Cross Cutting Themes
Conditions
Interventions
Haloperidol 2.5 mg intravenously or 0.5 ml normal saline intravenously 8 hourly for up to 14 days or until the patient screens negative for delirium for 48 hours using the CAM-ICU.
Follow up length:
Sponsors
West Hertfordshire Hospitals NHS Trust (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients requiring mechanical ventilation within 72 hours of admission 2. Male and female, aged 18 - 99 years
Exclusion criteria
Exclusion criteria: 1. Allergy to haloperidol 2. Chronic antipsychotic use 3. QTc greater than 500 msecs 4. History of torsades de pointes 5. Family history of dystonic reactions 6. Moribund and not expected to survive 7. Uncomplicated elective surgery 8. Expected to stay less than 48 hours 9. Moderate/severe dementia 10. Pregnancy 11. Parkinsons disease 12. Structural brain damage 13. History of neuroleptic malignant syndrome 14. Patients who do not understand English
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Delirium/coma free days, measured at 14 days | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Incidence of delirium 2. Delirium/coma free days in first 28 days 3. Number of ventilator free days at 28 days 4. Length of critical care and hospital stay 5. Mortality and cause of death at 6 months 6. Organ failure free days 7. Cognitive decline 8. Health related quality of life | — |
Countries
United Kingdom
Outcome results
None listed